Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEGA: FOLFOX with AMG 102 or Panitumumab in Gastroesophageal Adenocarcinoma
NCT01443065Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jan 2011
- Primary completion
- Mar 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab, rilotumumab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Unicancer. Started Jan 2011; status: completed.
02
Drugs
panitumumabrilotumumab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01443065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01443065.